Subscribe to RSS
DOI: 10.1055/s-2006-925198
Effects on the Male Endocrine System of Long-term Treatment with Gonadotropin-releasing Hormone Agonists and Estrogens in Male-to-Female Transsexuals
Publication History
Received 18 August 2005
Accepted after revision 5 October 2005
Publication Date:
27 April 2006 (online)
![](https://www.thieme-connect.de/media/hmr/200603/lookinside/thumbnails/10.1055-s-2006-925198-1.jpg)
Abstract
We studied hormonal changes resulting from long-term treatment with gonadotropin-releasing hormone agonist and 17β estradiol valerate in 40 healthy middle-aged male-to-female transsexuals over a period of two years. All of the participants received injections of 3.8 mg goserelin acetate every four weeks in combination with 6 mg oral 17β estradiol valerate per day for cross-sex hormone treatment for male-to-female transsexuals. There was a significant reduction in the levels of serum luteinizing hormone and follicle-stimulating hormone to the hypogonadal stage. Mean testosterone levels decreased by 97 % to 0.52 and 0.59 nmol/l after 12 months and 24 months, respectively. There was a significant reduction in dehydroepiandrosterone sulfate by 37 % after 12 months and 43 % after 24 months, and androstendione by 29 % after 12 months and 27 % after 24 months, respectively. Cortisol levels were reduced by 43 % and 50 %, respectively. Estrogen levels were significantly increased from 77.51 to 677 after 12 months and 661 pmol/l after 24 months. Sex hormone-binding globulin and corticoid-binding globulin levels were significantly increased after 12 and 24 months. There was a significant decrease in all measured androgen fractions and cortisol during long-term treatment with gonadotropin-releasing hormone agonist and 17β estradiol valerate. Apart from suppression of testicular hormone production, one possible interpretation is that treatment with long-term gonadotropin-releasing hormone agonist and 17β estradiol valerate influences adrenal hormone levels in healthy middle-aged male-to-female transsexuals. Cortisol serum levels may be decreased due to estrogen-induced increase in corticoid-binding globulin.
Key words
Transsexuals - GnRH analogues - estrogen - adrenal hormones - testis
References
- 1 Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab. 2001; 86 5729-5736
- 2 Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M. Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment; in Japanese. Hinyokika Kiyo. 2003; 49 521-525
- 3 Eri L M, Haug E, Tveter K J. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. Scand J Clin Lab Invest. 1996; 56 319-325
- 4 Philip P A, Carmichael J, Tonkin K. et al . Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer. 1993; 67 379-382
- 5 Scher H I, Kelly W K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11 1566-1572
- 6 Kitahara S, Umeda H, Yano M. et al . Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J. 1999; 46 659-664
- 7 Spetz A C, Hammar M, Lindberg B, Spangberg A, Varenhorst E,. Scandinavian Prostatic Cancer Group-5 Trial Study . Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 2001; 166 517-520
- 8 Gerber G S, Zagaja G P, Ray P S, Rukstalis D B. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology. 2000; 55 97-101
- 9 Fiet J, Dore J C, Go A L, Ojasoo T, Raynaud J P. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy. Prostate. 1993; 23 291-313
- 10 Ayub M, Levell M J. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue. Clin Endocrinol (Oxf). 1990; 32 329-339
-
11 Hamburger C.
Endocrine treatment of male and female transsexualism. In: Green R, Money J (eds) Transsexualism and Sex Reassignment. Baltimore; Johns Hopkins Press 1969: 291-307 - 12 Harry Benjamin International Gender Dysphoria Association .The Harry Benjamin International Gender Dysphoria Association standards of care for gender identity disorders, 6th version (November 17th, 2001). http://http://www.hbigda.org/soc.html. Retrieved 2002
- 13 Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003; 88 3467-3473
- 14 Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol. 2003; 59 409-418
- 15 Futterweit W. Endocrine management of transsexual: hormonal profiles of serum prolactin, testosterone, and estradiol. N Y State J Med. 1980; 80 1260-1264
- 16 Asscheman H, Gooren L, Assies J, Smith J, De Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male to female transsexual people. Clin Endocrinol (Oxf). 1988; 28 583-588
- 17 Gooren L, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab. 1988; 66 444-446
- 18 Asscheman H, Gooren L, Eklund P. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989; 38 869-873
- 19 Van Kesteren P, Asscheman H, Megens J, Gooren L. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997; 47 337-342
- 20 Michel A, Mormont C, Legros J. A psycho-endocrinological overview of transsexualism. Eur J Endocrinol. 2001; 145 365-376
- 21 Khosla S, Melton L J 3rd, Atkinson E J, O’Fallon W M, Klee G G, Riggs B L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998; 83 2266-2274
- 22 Vermeulen A, Kaufman J M, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002; 5 98-102
- 23 Carreau S, Bourguiba S, Marie E. Testicular and blood steroid levels in aged men. Reprod Biol. 2004; 4 299-304
-
24 Tyrell J B, Aron D C, Forsham P H.
Glucocorticoids and adrenal androgens. In: Greenspan FS (ed) Basic and clinical endocrinology, 3rd ed. Englewood Cliffs, New Jersey; Prentice-Hall 1991: 323-362 - 25 Gregg D W, Allen M C, Nett T M. Estradiol-induced increase in number of gonadotropin-releasing hormone receptors in cultured ovine pituitary cells. Biol Reprod. 1990; 43 1032-1036
- 26 Dall’Asta C, Ballare E, Mantovani G. et al . Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: in vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Horm Metab Res. 2004; 36 578-583
- 27 Miyamura N, Tsutsumi A, Senokuchi H. et al . A case of ACTH-independent macronodular adrenal hyperplasia: simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocr J. 2003; 50 333-340
- 28 Aedo A R, Landgren B M, Diczfalusy E. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in postmenopausal women. Maturitas. 1990; 12 333-343
- 29 Kuhl H. Pharmacology of estradiol and estriol. Menopause Rev. 2000; 5 23-44
- 30 Lin A D, Chen K K, Lin A T. et al . Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer. J Chin Med Assoc. 2003; 66 735-740
- 31 Adlercreutz H, Tenhunen R. Some aspects of the interaction between natural and synthetic female sex hormones and the liver. Am J Med. 1970; 49 630-648
- 32 Aldinger K, Ben Menachem Y, Whalen G. Focal nodular hyperplasia of the liver associated with high-dosage estrogens. Arch Intern Med. 1977; 137 357-359
- 33 Mueller A, Dittrich R, Binder H, Kühnel W, Maltaris T, Hoffmann I, Beckmann M W. High Dose Estrogen Treatment Increases Bone Mineral Density in Male to Female Transsexuals Receiving Gonadotropin-Releasing Hormone Agonist in the Absence of Testosterone. Eur J Endocrinol. 2005; 153 107-113
Andreas Mueller
Department of Obstetrics and Gynecology · Erlangen University Hospital
Universitätsstrasse 21-23 · 91054 Erlangen · Germany
Phone: +49 (9131) 853 35 53
Fax: +49 (9131) 853 35 52
Email: andreas.mueller@gyn.imed.uni-erlangen.de